At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Publications demonstrate depth and breadth of Fluxion’s liquid biopsy technologies
Fluxion has been pioneering liquid biopsy technologies since 2009, so it’s not surprising that researchers globally use the technologies for ground-breaking research. The publications highlighted here demonstrate the breadth and depth of applications being developed using our platforms.
The authors were able to extract CTCs using IsoFlux and to detect a KRAS gene mutation from the CTCs. This same mutation was later found to be present in the solid tumor, and possibly explains the patient's lack of response to targeted therapy.
"We present the case of a recurrent nasoethmoidal ITAC informed as RAS and BRAF wild-type by standard real-time polymerase chain reaction methods and treated with first-line cetuximab and irinotecan without response. Circulating tumor cells coupled to highly sensitive DNA analyses unveiled a mutation in KRAS exon 2 codon 12. Subsequent studies in the primary tumor using BEAMing detected a mutation in the same codon, confirming the KRAS mutated status of the tumor, and possibly explaining the absence of treatment response. This case exemplifies how liquid biopsy can aid in the correct and real-time molecular characterization of tumors even in a rare nonmetastatic cancer of the head and neck."
This ASCO poster looks at the effect of tumor cell “molecular plasticity” on drug efficacy and resistance. The poster concludes that gene expression changes related to taxane resistance are also present in CTCs, so CTC liquid biopsies could be an effective assay for patient monitoring.
This poster is a study comparing CTC enrichment for IsoFlux vs another platform, CellSearch. It concludes that IsoFlux recovers a much higher number of CTCs and that IsoFlux recovers a sufficient number of CTCs to enable castPCR analysis (a high-sensitivity PCR approach).
In this new paper, the authors develop a PD-LI test for melanoma using CTCs isolated with IsoFlux. Note that melanoma requires a different set of antibodies than carcinomas. Here the authors use MCAM and MCSP using our custom antibody kit- another key benefit of IsoFlux.
In this paper IsoFlux is used to isolate and analyze CTCs from liver cancer patients. "Liquid biopsy allows detecting and enumerating CTCs, and even to analyze DNA mutations, thus offering direct and dynamic information concerning tumor biological behavior. "
In this Nature Communications paper, the authors utilize a novel malaria protein as a universal marker for CTC isolation.
“The data from this study clearly indicate that rVAR2 combined with the IsoFlux™ system results in markedly higher assay sensitivity, which could be an important factor in the clinic, as it reduces the number of cancer cases with false negative tests and potentially allows for CTC detection at earlier stages of disease. In addition, the increased sensitivity could make the rVAR2-based method suitable for risk monitoring in patients suffering from cancer types with reportedly low CTC levels as well as detection of minimal residual disease after therapy or surgical resection of a tumor.”
This paper showed improve CTC isolation efficiency using mesenchymal markers to capture the EMT phenotype in addition to EpCAM alone for the epithelial phenotype. We do have a standard kit for this, although in this case the authors used their own antibodies using our custom antibody kit.
This is a method development paper looking at isolation of CTCs from cryopreserved samples vs. fresh. The authors show that, while there is a performance drop-off with frozen cells, the drop-off is more severe for samples with a large number of cells where the drop-off is less of an issue.
"In conclusion, the present study applied a ready to use and commercially available instrument (IsoFlux) to confirm a statistically significant fractional uptake of presumably malignant cells from periampullary tumors during surgical resections aimed at cure, assessed in a limited number of patients with pancreatic malignancy. This finding may represent a future surgical model to define and characterize tumor cells that disappear across hepatico-lung compartments, which may in part represent tumor clones with high metastatic potential during pancreatic resection."